Activation of phosphodiesterase IV during desensitization of the A2A adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells
- PMID: 9282956
- DOI: 10.1046/j.1471-4159.1997.69031300.x
Activation of phosphodiesterase IV during desensitization of the A2A adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells
Abstract
Prolonged activation of an A2A adenosine receptor significantly inhibits the cellular response to subsequent stimulation (A2A desensitization). We have reported previously that activation of phosphodiesterase (PDE) contributes to A2A desensitization in PC12 cells. In the present study, we show that a type IV PDE (PDE4)-selective inhibitor (Ro 20-1724) effectively blocks the increase in PDE activity in desensitized cells. Thus, PDE4 appears to be the PDE specifically activated during A2A desensitization in PC12 cells. Prolonged treatment of PC12 cells with an A2A-selective agonist (CGS21680) leads to increased PDE4 activity in a dose-dependent manner, which can be blocked by an A2A-selective antagonist [8-(3-chlorostyryl)caffeine]. Using two PDE4 antibodies, we were able to demonstrate that the levels of two PDE4-immunoreactive bands (72 and 79 kDa) were increased significantly during A2A desensitization. Prolonged treatment with forskolin to elevate intracellular cyclic AMP contents also resulted in increased PDE4 activity. In addition, activation of PDE4 activity during A2A desensitization could be blocked by a protein kinase A (PKA)-selective inhibitor (H89) and was not observed in a PKA-deficient PC12 cell line (A123). Taken together, activation of PDE4 via a cyclic AMP/PKA-dependent pathway plays a critical role in dampening the signal of the A2A receptor.
Similar articles
-
Multiple mechanisms for desensitization of A2a adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells.Mol Pharmacol. 1993 Nov;44(5):950-8. Mol Pharmacol. 1993. PMID: 8246918
-
The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells.Neuropsychopharmacology. 2003 Jul;28(7):1317-27. doi: 10.1038/sj.npp.1300181. Epub 2003 Apr 30. Neuropsychopharmacology. 2003. PMID: 12784121
-
Regulation of adenylyl cyclase type VI activity during desensitization of the A2a adenosine receptor-mediated cyclic AMP response: role for protein phosphatase 2A.Mol Pharmacol. 1995 Jul;48(1):1-8. Mol Pharmacol. 1995. PMID: 7623763
-
Biochemical characteristics and cellular regulation of phosphodiesterase IV.Agents Actions Suppl. 1993;43:51-71. doi: 10.1007/978-3-0348-7324-6_5. Agents Actions Suppl. 1993. PMID: 8396319 Review.
-
Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?Trends Pharmacol Sci. 1997 May;18(5):164-71. doi: 10.1016/s0165-6147(97)01049-3. Trends Pharmacol Sci. 1997. PMID: 9184477 Review.
Cited by
-
The D2 Dopamine Receptor Interferes With the Protective Effect of the A2A Adenosine Receptor on TDP-43 Mislocalization in Experimental Models of Motor Neuron Degeneration.Front Neurosci. 2018 Mar 20;12:187. doi: 10.3389/fnins.2018.00187. eCollection 2018. Front Neurosci. 2018. PMID: 29615863 Free PMC article.
-
PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.Biochem J. 2003 Feb 15;370(Pt 1):1-18. doi: 10.1042/BJ20021698. Biochem J. 2003. PMID: 12444918 Free PMC article. Review.
-
GSK3β negatively regulates TRAX, a scaffold protein implicated in mental disorders, for NHEJ-mediated DNA repair in neurons.Mol Psychiatry. 2018 Dec;23(12):2375-2390. doi: 10.1038/s41380-017-0007-z. Epub 2018 Jan 3. Mol Psychiatry. 2018. PMID: 29298990 Free PMC article.
-
The antidepressant and antiinflammatory effects of rolipram in the central nervous system.CNS Drug Rev. 2001 Winter;7(4):387-98. doi: 10.1111/j.1527-3458.2001.tb00206.x. CNS Drug Rev. 2001. PMID: 11830756 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials